OneSource Specialty Pharma and Xbrane Biopharma Forge Biosimilars Manufacturing Partnership; Tech Transfer to Bangalore Facility Announced

OneSource Specialty Pharma Ltd has entered a landmark biosimilars manufacturing partnership with Sweden’s Xbrane Biopharma AB, marking a significant step in global biotech collaboration. As part of the agreement, Xbrane will transfer technology for key biosimilar products to OneSource’s state-of-the-art facility in Bangalore, enabling local production and expanding access to advanced biologics in India and beyond.

 

Key Highlights

 

Biosimilars Manufacturing Partnership:

OneSource Specialty Pharma and Xbrane Biopharma have announced a strategic alliance focused on the development and manufacturing of biosimilars. The partnership leverages Xbrane’s patented platform technology and OneSource’s extensive CDMO (Contract Development and Manufacturing Organization) capabilities.

 

Technology Transfer to Bangalore:

Xbrane will transfer its biosimilar product technologies—including those for Lucamzi (biosimilar to Lucentis) and Xdivane (biosimilar to Opdivo)—to OneSource’s Bangalore facility. This move will facilitate local manufacturing, regulatory filings, and commercialization in high-growth markets.

 

Equity Investment and Strategic Alignment:

As part of the collaboration, OneSource Specialty Pharma is subscribing to shares in Xbrane Biopharma, participating in a SEK 240 million directed share issue alongside other institutional investors. The funds will support Xbrane’s FDA regulatory process for Lucamzi, further development of Xdivane, and working capital needs.

 

Operational Synergies:

OneSource, with five globally approved manufacturing facilities and a proven compliance track record, will now be positioned to supply complex biologics and biosimilars to global pharma companies seeking efficient, end-to-end solutions.

 

Market Impact:

The partnership is expected to accelerate the availability of affordable biosimilars in India and emerging markets, supporting broader access to life-saving therapies and strengthening both companies’ global footprints.

 

Leadership Commentary:

Xbrane’s CEO Martin Åmark highlighted the financial flexibility and strategic reach gained through the partnership, while OneSource’s leadership emphasized the move as a validation of its world-class manufacturing and regulatory capabilities.

 

Insight

This collaboration between OneSource Specialty Pharma and Xbrane Biopharma is set to reshape the biosimilars landscape in India, bringing advanced biologics manufacturing and technology transfer to the forefront. The partnership not only enhances OneSource’s CDMO platform but also positions both companies for accelerated growth in the global biosimilars market.

 

Source:TradingView/Reuters.Biostock,TradingView, MarketScreener, Moneylife